Gastrointestinal Cancer Research - Penn State Cancer Institute
Gastrointestinal Cancer Research
Research into gastrointestinal cancer at Penn State Cancer Institute is conducted by our dedicated gastrointestinal cancer team. See current clinical trials and members of that team here.
Clinical Trials
CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: a prospective, randomized, double-blind, multi-center clinical trial
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
The COVID-19 and Cancer Consortium (CCC19) Registry
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Amanda | Cooper | MD | ||
 |
Michael | Deutsch | MD | ||
 |
Walter | Koltun | MD | ||
 |
Abraham | Mathew | MD | ||
 |
Thomas | McGarrity | MD | ||
 |
Kevin | McKenna | MD | ||
 |
Matthew | Moyer | MS, MD | ||
 |
Nabeel | Sarwani | MD | ||
 |
Ian | Schreibman | MD | ||
 |
Jeffrey | Scow | MD | ||
 |
Leonard | Tuanquin | MD | ||
 |
Nelson Shu-Sang | Yee | MD, PhD, RPh |
Research into gastrointestinal cancer at Penn State Cancer Institute is conducted by our dedicated gastrointestinal cancer team. See current clinical trials and members of that team here.
CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: a prospective, randomized, double-blind, multi-center clinical trial
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
The COVID-19 and Cancer Consortium (CCC19) Registry
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Amanda | Cooper | MD | ||
|
Michael | Deutsch | MD | ||
|
Walter | Koltun | MD | ||
|
Abraham | Mathew | MD | ||
|
Thomas | McGarrity | MD | ||
|
Kevin | McKenna | MD | ||
|
Matthew | Moyer | MS, MD | ||
|
Nabeel | Sarwani | MD | ||
|
Ian | Schreibman | MD | ||
|
Jeffrey | Scow | MD | ||
|
Leonard | Tuanquin | MD | ||
|
Nelson Shu-Sang | Yee | MD, PhD, RPh |